Breast Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are able and willing to provide written consent before any trial procedures begin
- People with a single tumour in one breast, confirmed by biopsy, that is either a specific hormone-sensitive subtype called Luminal B (with or without HER2 involvement) or a type that tests negative for oestrogen receptors
- People whose tumour was larger than 1 cm and smaller than 5 cm at diagnosis, with no sign of cancer spread to other organs
- People who had a small surgical clip placed in the tumour before starting chemotherapy, to mark its location
- People who received chemotherapy before surgery (called neoadjuvant chemotherapy) and whose breast imaging (ideally MRI, or ultrasound if MRI is not available) shows a complete or near-complete disappearance of the tumour, confirmed within 28 days before joining the trial
- People whose original tumour site can be reached for a tissue sample (biopsy)
- People aged 18 or older, of any gender
- People who are in suitable health to undergo breast cancer surgery
- People with a history of a previous cancer may be eligible, provided that the previous cancer is very unlikely to affect the safety or results of this trial (confirm with trial site)
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose breast cancer has spread to other parts of the body (metastatic cancer)
- People with breast cancer appearing in multiple areas or more than one focus within the breast
- People with inflammatory breast cancer
- People whose cancer is classified as Luminal-A type, or is considered low risk based on a specialised genetic tumour test
- People whose imaging after chemotherapy shows clear signs of remaining cancer in the breast
- People who had calcium deposits (microcalcifications) in or around the tumour larger than 2 cm at the time of diagnosis
- People who have already had radiation therapy or surgery to the affected breast before this trial
- People with serious medical, psychiatric, psychological, family, or personal circumstances that, in the treating doctor's judgement, could interfere with participation, treatment, or follow-up, or could put the person at significant risk
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christoph Tausch, MD, Brust-Zentrum, Zürich
Phone: +41 44 387 9545
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
Primary endpoints
Sensitivity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.